Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2013 09:30 ET | Source: Argos Therapeutics

Argos Therapeutics Welcomes Jean Lamarre to Board of Directors

DURHAM, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
March 04, 2013 08:01 ET | Source: Argos Therapeutics

Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients

DURHAM, N.C., March 4, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
February 14, 2013 08:01 ET | Source: Argos Therapeutics

Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma

DURHAM, N.C., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
January 28, 2013 08:01 ET | Source: Argos Therapeutics

Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum

DURHAM, N.C., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
November 15, 2012 14:19 ET | Source: Argos Therapeutics

Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of Its RNA-Based Immunotherapies

DURHAM, N.C., Nov. 15, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
November 02, 2012 08:00 ET | Source: Argos Therapeutics

Southeast BIO Recognizes Argos Therapeutics with the "2012 Southeast BIO Deal of the Year: Venture Capital Transaction" Award

DURHAM, N.C., Nov. 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
October 11, 2012 10:49 ET | Source: Argos Therapeutics

Argos Therapeutics Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003

DURHAM, N.C., Oct. 11, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
October 08, 2012 08:04 ET | Source: Argos Therapeutics

Argos Therapeutics' Phase 3 ADAPT Study for AGS-003 Highlighted During 11th Annual International Kidney Cancer Symposium

DURHAM, N.C., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
September 27, 2012 08:01 ET | Source: Argos Therapeutics

Argos Therapeutics Invited to Present at Two Biotech Industry Conferences

DURHAM, N.C., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
September 20, 2012 08:01 ET | Source: Argos Therapeutics

Argos Therapeutics to Present at Noble Financial Capital Markets' BIOX Life Sciences Exposition

DURHAM, N.C., Sept. 20, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...